Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropsychiatric and Neurological Disorder Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KCNC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KCNC1 ECD Recombinant Protein Sequence Verified. High Purity (>95%), Endotoxin Controlled. |
View KCNC1 Products |
| Gene Delivery | KCNC1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for electrophysiology assays. |
View KCNC1 Products |
| Benchmark Ab | Anti-KCNC1 Recombinant Antibody Recombinant positive control for expression validation. |
View KCNC1 Products |
| Validator | KCNC1 siRNA Set For target knockdown and specificity verification. |
View KCNC1 Products |
| Related Target A | KCNC2 (Kv3.2) Homologous channel; critical for off-target selectivity screening in neuropsychiatric drug discovery. |
View KCNC2 Products |
| Related Target B | KCNC3 (Kv3.3) Subfamily member associated with spinocerebellar ataxia; required for counter-screening panels. |
View KCNC3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Multi-pass Membrane Protein | High-titer Lentivirus for stable cell line generation to preserve native 6-transmembrane structure. |
| Subfamily Off-target Screening (Kv3.1 vs Kv3.2/3.3) | Sequence-verified homologous target panel (KCNC1, KCNC2, KCNC3) available. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live KCNC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KCNC1 therapeutics is intensifying, with major players shifting focus from traditional ion channel blockers to positive allosteric modulators (PAMs). As first-generation therapies reach the clinic, the next wave of R&D is targeting precision medicine approaches for rare genetic encephalopathies and cognitive deficits in schizophrenia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PAM) | Autifony Therapeutics, Lundbeck | Schizophrenia, Hearing Loss, Fragile X | Functional Electrophysiology (Need Lentivirus for Stable Cell Lines) |
| Small Molecule (NAM) | Shionogi, Academic Institutions | Epilepsy (EPM12, R320H mutation) | Mutant vs WT Selectivity Assay (Need Custom Mutant Lentivirus) |
| Antibody/Biologics | Emerging Biotechs | Neuropathic Pain | Epitope Mapping & Binding (Need Sequence-Verified ECD Proteins) |